In fact, GIMM’s structure includes two core components: GIMM Discovery, which focuses on fundamental research and the pursuit of scientific breakthroughs, and GIMM Care, which emphasizes the application of scientific knowledge to improve healthcare and quality of life. Through the Care initiative, GIMM aims to revolutionize clinical and translational research by creating a pioneering Center of Excellence in Portugal. This people-centered, data-driven model brings together a diverse range of stakeholders to collaboratively address key health challenges, accelerate the translation of research into clinical practice, and foster innovative solutions that respond to the most urgent healthcare needs.

Through these efforts, GIMM stands at the forefront of global efforts to enhance scientific understanding and improve human health, making it an ideal partner for those committed to supporting cutting-edge research with profound societal impact.

Frontier Research

At GIMM, we position our science at the forefront of frontier research by embracing a bold and transformative approach to discovery that integrates fundamental and applied research. Our unique structure, divided into GIMM Discovery and GIMM Care, embodies this vision by unifying curiosity-driven exploration with a focus on real-world healthcare solutions.
GIMM Discovery is the heart of our fundamental research, where scientists are encouraged to pursue groundbreaking ideas that push the boundaries of our understanding of biology and human health. This component thrives on curiosity-driven research, fostering a culture where curiosity, innovative thinking and interdisciplinary collaboration are encouraged. By nurturing this exploratory spirit, GIMM Discovery not only advances our knowledge but also lays the groundwork for future innovations that can have profound impacts on science and society.
GIMM Care, on the other hand, is dedicated to translating these fundamental discoveries into practical applications that directly address healthcare challenges. By focusing on clinical and translational research, GIMM Care aims to shorten the path from fundamental scientific discoveries to real-world health solutions. This component brings together a diverse network of stakeholders, including clinicians, researchers, patients, and industry partners, to co-create innovative, data-driven approaches that enhance health outcomes and promote equity.
The synergy between GIMM Discovery and GIMM CARE ensures a dynamic flow of knowledge and innovation, where fundamental research informs applied projects, and practical needs inspire new scientific questions. This interconnected approach enables GIMM to rapidly adapt to evolving healthcare challenges, driving both scientific excellence and societal impact. By bridging the divide between curiosity-driven research and its application, we position GIMM not just as a leader in molecular medicine but as a catalyst for transformative change in global health.
Beyond the walls of GIMM, we actively shape the national and European R&D landscape through collaboration, promoting excellence in research and training, and engaging society in scientific and cultural development. Our efforts extend beyond traditional boundaries, pushing the limits of scientific knowledge and making a profound impact on global health and well-being. By focusing on ensuring these values and aims, GIMM stands at the forefront of frontier research, driving transformative change and advancing the frontiers of molecular medicine.

For over a decade, the LCSB has established a state-of-the-art infrastructure and developed skills in several fields, such as genetics, metaproteomics, enzymology and cheminformatics. We foster interdisciplinarity because we strongly believe that complex problems can only be solved when the best minds from different disciplines come together and form a team.

We work together with scientific partners worldwide and carry out collaborative projects with research-oriented companies and hospitals, to accelerate the translation of research results into clinical applications and to tackle the growing issue represented by neurodegenerative diseases worldwide.

Research projects
– experimental oncology – study of environmental, genetic, epigenetic and (patho)physiological mechanisms of carcinogenesis and cancer progression,
research and development of new approaches to cancer prevention, diagnosis and therapy.
– experimental endocrinology – research in the fields of endocrinology, neuroendocrinology and psychiatry, cardiology, exercise physiology and integrative (patho)physiology of metabolic disorders, as well as genetics and DNA diagnostics of rare disorders with focus on direct translation into the clinical practice. – – virology – research on epidemiology, pathogenesis and immunology and of viral and rickettsial infections, research and development of new diagnostic and therapeutic approaches, development of analytical methods for practice.
-neurobiology – research of central nervous system focused on vascular and traumatic disorders, mechanisms of injury, neuroprotection, and new approaches to regeneration of nerve tissue.

S. Pastorekova: Role of the CA IX ectodomain in tumor growth and metastasis
B. Smolkova: Identification of biological markers for prevention and translational medicine in pancreatic cancer
J. Ukropec: Molecular mediators of the response to complex lifestyle intervention in patients with obesity: Regulation of metabolic flexibility in vitro and in vivo
B. Ukropcova: Ameliorating Effects of Aging by Physical Exercise: Molecular, Metabolic and Structural Adaptations, Multi-Organ Integrative Approach
B. Klempa: Zoonoses Emergence across Degraded and Restored Forest Ecosystems (ZOE).

The Cluster of Excellence CMFI brings together researchers from different disciplines such as infection biology, immunology, bioinformatics, pharmaceutical biology, antibiotics research, molecular and medical microbiology, biotechnology, environmental biology, systems biology, chemistry, and medical history and ethics. Their common goal is to elucidate the mechanisms of interaction between beneficial and harmful bacteria and the host in order to develop novel targeted therapeutic and anti-infective treatments.

The CMFI is one of more than 50 Clusters of Excellence funded by German federal and state governments as part of the Excellence Strategy to sustainably strengthen Germany as a center of science, improve its international competitiveness and make cutting-edge research at German universities visible. In addition to the University of Tübingen, the Max Planck Institute for Biology and the University Hospital Tübingen are involved in the CMFI.

Its main research directions include Immunity & Inflammation, Neuroscience, Cancer Biology, RNA Biology & Epigenetics, Bioinformatics & Computational Biology. Additionally, BSRC FLEMING has recently established its frontier research in Biomolecular Engineering & Synthetic Biology with a European Research Area chair (ERA Chair), Dr. Georgios Skretas. These research directions reflect the work of its group leaders and serve as links between the two FLEMING Institutes: Institute for Bioinnovation (IBI) and Institute for Fundamental Biomedical Research (IFBR). The focus of IFBR is on unravelling the molecular and cellular basis of disease via novel animal models of human pathologies, while IBI’s vision is to advance fundamental research achievements towards innovative translational biotechnologies and drug development.
BSRC FLEMING’s strength and international recognition arises from pioneering research towards understanding the molecular and cellular basis of human diseases, and development and validation of relevant animal models of chronic inflammatory diseases, neurodegenerative disorders, metabolic diseases, cancer and autoimmune syndromes, among others, and the development of new approaches for their diagnosis and treatment, using transdisciplinary approaches and state-of the art facilities and technologies. It is of note that several of its researchers have been included in the list of outstanding research leaders in Europe awarded ERC grants.
The center also coordinates two major Research Infrastructures (RIs) for modeling human diseases and bioinformatics/biocomputing resources, while it participates in personalized medicine, precision oncology and bioimaging RIs.

IDIBAPS research is organized into research areas and multidisciplinary programs.

5 Research Areas and 3 transversal groups:
1. Biological aggression and response mechanisms
2. Respiratory, cardiovascular and renal pathobiology and bioengineering
3. Liver, digestive system and metabolism
4. Clinical and experimental neuroscience
5. Oncology and haematology
6. Transversal research groups focusing on primary care, pharmacology and nursing

Multidisciplinary Programs:
1. Transitional cancer research program
2. Lymphoid neoplasms program
3. Synaptic autoimmunity in neurology, psychiatry and cognitive neuroscience program

Among the multiple research groups, we would like to highlight the following research lines, supported by ERC grants, for the FRONTIERS Science Journalism Residency Program:
– Neuronal control of metabolism directed by Marc Claret, Principal Investigator of MITOSENSING project: https://cordis.europa.eu/project/id/725004
– Cortical circuit dynamics directed by Jaime de la Rocha, Principal Investigator of PRIORS project: https://cordis.europa.eu/project/id/683209
– Molecular pathology of lymphoid neoplasms directed by Elías Campo, Principal Investigator of BCLLatlas project: https://cordis.europa.eu/project/id/810287

Furthermore, the work environment fosters a strong culture of science communication, offering fellows a full immersion into the realm of scientific outreach. Fellows will have the opportunity to develop essential communication skills, create engaging content, and broaden the reach of scientific discoveries to the general public. This fellowship is ideal for professionals interested in exploring the intersection of science, journalism, and digital communication while collaborating with a multidisciplinary and inspiring team.

This offers an immersive experience within the vibrant ecosystem of CNC-UC / CiBB, providing fellows with unique access to the forefront of biomedical research and science communication. Fellows will be fully integrated into the CNC-UC / CiBB community and will have the opportunity to attend weekly scientific seminars and thematic retreats, gaining invaluable insights into cutting-edge research across various biomedical disciplines. They will actively participate in the institution’s science communication dynamics, engaging in various outreach activities and gaining access to scientific platforms to observe experiments and scientific endeavors firsthand.

More about CiBB
With the largest critical mass of researchers in the Centre Region of Portugal, internationally recognized and linked to the Faculties of Pharmacy, Medicine, Sciences and Technology and Economics, as well as to the Institute of Interdisciplinary Research and to the Coimbra University Hospital, CiBB has a high-level of scientific production and attracts talent and funding at national and international levels.

The CiBB stands as the flagship of Biomedical and Biotechnology Sciences at the University of Coimbra (UC). It is the largest R&D Unit in the center region of Portugal and the sole UC-coordinated Associate Laboratory (top 100% evaluation), welcoming circa 700 members.
CiBB comprises 37 dynamic and multidisciplinary research groups, dedicated to understanding how and why diseases develop, particularly those associated with aging, and translating this understanding into clinical applications and technological breakthroughs.
Structured around four thematic pillars, CIBB’s mission spans diverse areas:
1. Neuroscience and Disease: Delving into brain function and dysfunction in disorders such as neurodegenerative diseases, neuropsychiatric conditions, and vision impairments.
2. Metabolism, Aging, and Disease: Investigating the cellular and molecular underpinnings of metabolic dysfunction and aging, and their impact on age-related diseases.
3. Innovative Therapies: Harnessing the potential of stem cells, genetic interventions, and pharmaceuticals to pioneer new treatments for neurodegenerative, cardiovascular, oncological, and infectious conditions.
4. Healthcare Challenges: Tackling healthcare challenges by promoting evidence-based decision-making, engaging citizens, and finding innovative solutions for aging-related questions.
CiBB is committed to nurturing talent, through robust international training programs at the master’s and doctoral levels. Additionally, CiBB bridges the gap between research and society through effective communication and public engagement initiatives.
In collaboration with the Coimbra University Hospital and its Clinical Academic Center, CiBB leverages its strong ties to clinical practice, facilitating the translation of fundamental research findings into clinical benefits. Moreover, CiBB invests on the transformation of scientific breakthroughs into intellectual property, fostering technology transfer and the creation of economic value.

Note: We are open to developing projects that encompass a broader scope, involving communication across different areas of the center, and/or focusing on specific ongoing research projects within the center.

In order to examine microbial natural products and to understand infectious diseases better, we combine both areas of research. We aim to elucidate how microorganisms produce both pathogenic substances and pharmacologically relevant components. Beyond that, these substances of micro-organisms serve as instruments of communication among themselves. Another module of our research is the interaction of pathogenic microorganisms with their host. We are interested in investigating the methods and tricks that both parties use in this process.

Numerous individual joint projects enable us to acquire new knowledge in the field of biosynthesis and the function of natural products. We use this knowledge to develop innovative ingredients for the diagnosis and therapy of illnesses, including new anti-infectives. Implementing our research results and the models derived thereof, we contribute to the development of a systems biology of infections.

Under the central theme of “population-based prevention research in the life-course,” the institute conducts interdisciplinary epidemiological health research on the national and international level. It develops innovative methods and utilizes diverse data sources to study significant health disorders and to evaluate preventive measures and strategies. In addition, BIPS significantly contributes to the establishment of research infrastructures of national and international importance. To this end, BIPS is also committed to the expansion of research data management and the FAIRification of research data as an important basis of Open Science and Open Data.

For many years, strengthening prevention has been a key scientific, social, and political objective. BIPS is dedicated to achieve this goal with high-quality research based upon methodological research investigating epidemiological questions with a focus on the development of epidemiological and statistical methods. The institute emphasizes the particular importance of the life-course perspective for the health of individuals and the population as a whole with its focus on long-term studies. Research at the institute provides important insights to ensure and improve health and well-being with measures that begin early and are related to transition periods within the life-course.

Discovery: This branch of research investigates the highly complex interactions of different immune cells—with each other and with the organism’s cells—to understand how the immune system maintains the health of the organism.
Translation: This area focuses specifically on the preclinical development of immune-cell therapeutics. This includes the identification, differentiation, expansion, and preclinical testing of therapeutically relevant immune cell populations.
Clinical Application: At the LIT, our core focus is on the clinical translation of scientific findings: We therefore place significant emphasis on the development and roll out of clinical trials and focus on the clinical implementation of the results.